

Dealdoc**Acquisition agreement for CaridianBCT**

Terumo
CaridianBCT
Gambro

Mar 07 2011

Acquisition agreement for CaridianBCT

Companies:	Terumo CaridianBCT Gambro
Announcement date:	Mar 07 2011
Deal value, US\$m:	2630.0 : sum of transaction

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

Announcement date:	Mar 07 2011
Industry sectors:	Pharmaceutical Medical device

Financials

Deal value, US\$m:	2630.0 : sum of transaction
---------------------------	-----------------------------

Termsheet

Gambro AB unit is selling its blood technology business CaridianBCT to Japanese medical technology firm Terumo Corporation (4543.TO) for \$2.63 billion.

Press Release

14 April 2011

Terumo Corporation Completes Acquisition of CaridianBCT

TOKYO--(BUSINESS WIRE)--Terumo Corporation (Head Office: Shibuya-ku, Tokyo; President: Yutaro Shintaku - hereinafter "Terumo") announced today the completion of the previously announced pending acquisition of CaridianBCT Holding Corp. (Head Office: Colorado, the United States - hereinafter "CaridianBCT").

The acquisition of CaridianBCT is part of Terumo's core strategy to achieve the long-term growth target revenue of ¥1 trillion by the year 2020 and constitutes a new growth pillar for the company.

The acquisition also positions Terumo's blood management business as the global leader in the blood bank technology industry with revenues in excess of \$830 million. The combined organization will be able to offer blood bank customers a wider range of blood processing technologies as well as continue product portfolio expansion in the adjacent hospital and biotechnology customer segments.

David Perez, the current President and CEO of CaridianBCT, has been named President and CEO of the combined blood management business of CaridianBCT and Terumo. The global headquarters will be located in Colorado, U.S.

"This is an exciting moment for both companies. We are uniting two industry leaders, both strongly focused on customers and patients with similar cultures and value systems. Both organizations share a passion for innovation and a commitment to developing and delivering customer quality and satisfaction," said Mr. Perez. "Together, we are poised to be the undisputed global industry leader. I believe we have what it takes – great people, an established brand, a strong product portfolio, an expanding customer base, an innovation pipeline and a strong balance sheet."

The financials of CaridianBCT will be included within both on the balance sheet and profits and losses of Terumo, on consolidated basis, starting with the first quarter of fiscal 2012 (the business year ending March 31, 2012).

About CaridianBCT:

CaridianBCT is the leading global provider of innovative technologies and services in automated blood collections, pathogen reduction technologies, whole blood processes and therapeutic apheresis and cell therapy systems. The company serves patients through its commitment "For Better Blood and Better Lives" by developing and commercializing products that serve global customers in the blood banking, therapeutic apheresis and transfusion medicine industries. For more information, visit www.caridianbct.com.

About Terumo Corporation

Terumo Corporation is a premier global medical device company with annual sales of more than \$3.5 billion for the fiscal year ending March 31, 2011. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, such as syringes, blood bags and IV solutions. Terumo has the biggest share of the world markets for angiography guide wires and perfusion products and is a leading developer of interventional products, such as catheters and stents. For more information, visit www.terumo.com.

7 March 2011

Terumo: Notice Regarding the Acquisition of CaridianBCT

March 7, 2011 -- Terumo Corporation (Head Office: Shibuya-ku, Tokyo; President: Yutaro Shintaku - hereinafter "Terumo") today announced that it has entered into a Stock Purchase Agreement to acquire all outstanding shares (the "Acquisition") of CaridianBCT Holding Corp. (Head Office: Colorado, the United States - hereinafter "CaridianBCT"), a leading global provider in the blood transfusion industry as follows:

Ever since it made its first entry into the blood transfusion market in the 1960s, Terumo has been expanding both domestically and internationally, especially in blood bag products, and now has grown into the No.5 blood transfusion player globally. The blood transfusion industry, which showed only modest growth in the past, is now transforming into a dynamic high-growth business segment

There is rising global demand for blood transfusion products, in part due to the aging of the population in developed nations (and increased need for treatments requiring blood products) and, in emerging economies, it is the rapid development of healthcare infrastructure.

In this fast-changing environment, Terumo is focused on expanding its blood transfusion business, as part of its core strategy to achieve the long-term objective of "target revenue of 1 trillion yen within 10 years." The acquisition of CaridianBCT will transform Terumo's transfusion business by expanding Terumo's offerings into complementary business lines and geographies. CaridianBCT is one of the world's leading providers in blood processing technologies for blood banks, hospitals, biotech and therapeutic applications. This transaction will allow Terumo to offer a wider range of blood processing technologies and greatly expand Terumo's geographic presence, particularly in the key North American market.

With this Acquisition, it is possible for Terumo to dramatically drive its growth strategies to achieve the target revenue of 1 trillion yen.

7 March 2011

Investor Holding Sells CaridianBCT To Terumo For \$2.63 Billion

STOCKHOLM -(Dow Jones)- Sweden's Investor AB (INVE-B.SK) Monday said its Gambro AB unit is selling its blood technology business CaridianBCT to Japanese medical technology firm Terumo Corporation (4543.TO) for \$2.63 billion.

The deal will boost Investor's net asset value by about 4.2 billion Swedish kronor (\$661.4 million).

CaridianBCT is one of two remaining independent entities within Gambro AB, which focuses on kidney and liver dialysis and is jointly controlled by Investor, the main investment arm of the Wallenberg family, and by private equity fund EQT IV.

Investor and EQT bought Gambro in 2006 and split the company into three separate units, including Gambro Healthcare which was sold in 2007. With the sale of CaridianBCT, Gambro will be the sole remaining entity. It will use the proceeds to reduce its debt to about SEK7.6 billion, calculated pro forma as of Dec. 31, 2010.

The price corresponds to about 15 times CaridianBCT's earnings before interest, taxes, depreciation and amortization, Investor said.

Filing Data

Not available.

Contract

Not available.